| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
IC50: 6.62 μM (JMJD7)[1]
JMJD7-IN-1 likely targets JMJD7 (Jumonji domain-containing protein 7), a histone demethylase that removes methyl groups from histone proteins, thereby regulating gene expression. Histone demethylases are emerging as important therapeutic targets in cancer and other diseases. By inhibiting JMJD7, this compound may modulate gene expression patterns that affect cell proliferation, differentiation, and survival. However, specific target information has not been detailed in the available literature. |
|---|---|
| ln Vitro |
JMJD7-IN-1 (0.1-1000 μM) has an IC50 of 6.62 μM and suppresses JMJD7 activity in a dose-dependent manner[1]. JMJD7-IN-1 binds to JMJD7 effectively, having an IC50 of 3.80 μM [1]. T-47d, SK-BR-3, Jurkat, and Hela cell proliferation is inhibited by JMJD7-IN-1 (72 h), with IC50s of 9.40 μM, 13.26 μM, 15.03 μM, and 16.14 μM, respectively[1].
In vitro data for JMJD7-IN-1 is not publicly available. As a JMJD7 inhibitor, it would be expected to inhibit JMJD7 demethylase activity, leading to changes in histone methylation and gene expression. The compound may have been tested in cell-based assays or biochemical screens to characterize its activity. However, specific in vitro activity data, including IC50 values or efficacy measurements, have not been reported in the available literature. |
| ln Vivo |
In vivo data for JMJD7-IN-1 is not publicly available. As a research compound, it may have been tested in animal models for pharmacokinetic or efficacy studies, but these results have not been published or are not accessible in the current literature. Researchers interested in the in vivo properties of JMJD7-IN-1 should consult the original research articles or contact the supplier for additional information.
|
| Enzyme Assay |
The in vitro JMJD7 inhibition assay for JMJD7-IN-1 would use recombinant JMJD7 enzyme and a histone peptide substrate. Demethylase activity is measured using fluorescence-based or mass spectrometry-based detection methods, and IC50 values are calculated from dose-response curves. Selectivity profiling against other JMJD family members would be performed to determine the compound's specificity.
|
| Cell Assay |
Cellular assays for JMJD7-IN-1 are conducted in cancer cell lines or other relevant cell models. Cells are treated with varying concentrations of the compound, and histone methylation levels are measured by Western blotting using specific antibodies. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. Gene expression changes are analyzed by qPCR or RNA sequencing.
|
| Animal Protocol |
In vivo studies for JMJD7-IN-1 would typically involve xenograft mouse models of cancer or other disease models where JMJD7 plays a role. The compound would be administered via oral or intraperitoneal routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring tumor growth inhibition or disease phenotype improvement. However, specific published in vivo protocols for JMJD7-IN-1 are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for JMJD7-IN-1 is not publicly available. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life, bioavailability, and clearance have not been reported in the available literature. Researchers interested in the pharmacokinetic properties of JMJD7-IN-1 should consult the original research articles or contact the manufacturer.
|
| Toxicity/Toxicokinetics |
Toxicity data for JMJD7-IN-1 is not publicly available. As a research compound, its safety profile would typically be evaluated in in vitro cytotoxicity assays and in vivo tolerability studies. However, specific toxicity data has not been reported in the available literature. As with all research compounds, JMJD7-IN-1 is intended for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
JMJD7-IN-1 (CAS 311316-96-8) is a research compound that is likely an inhibitor of JMJD7, a Jumonji domain-containing histone demethylase. It is used in epigenetics and cancer research to study the role of histone demethylation in gene regulation and disease. Further information on this compound would require access to specialized chemical databases or the original literature. The compound is intended for research use only.
|
| Molecular Formula |
C16H8CL2N2O4
|
|---|---|
| Molecular Weight |
363.1517
|
| Exact Mass |
361.986
|
| CAS # |
311316-96-8
|
| PubChem CID |
1514078
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
487
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C(C([H])=C([H])C=1C(=O)OC1C([H])=C([H])C(=C2C([H])=C([H])C([H])=NC2=1)[N+](=O)[O-])Cl
|
| InChi Key |
YKPUGYXWOBGQLL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H8Cl2N2O4/c17-9-3-4-10(12(18)8-9)16(21)24-14-6-5-13(20(22)23)11-2-1-7-19-15(11)14/h1-8H
|
| Chemical Name |
(5-nitroquinolin-8-yl) 2,4-dichlorobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 8.33 mg/mL (22.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7537 mL | 13.7684 mL | 27.5368 mL | |
| 5 mM | 0.5507 mL | 2.7537 mL | 5.5074 mL | |
| 10 mM | 0.2754 mL | 1.3768 mL | 2.7537 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
